Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Accelerate Diagnostics's Enterprise Value is MXN946.6 Mil.
Accelerate Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-685.7 Mil. Therefore, Accelerate Diagnostics's EV-to-EBIT ratio for today is -1.38.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Accelerate Diagnostics's Enterprise Value is MXN946.6 Mil.
Accelerate Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-621.2 Mil. Therefore, Accelerate Diagnostics's EV-to-EBITDA ratio for today is -1.52.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Accelerate Diagnostics (MEX:AXDX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Accelerate Diagnostics's current Enterprise Value is MXN946.6 Mil.
Accelerate Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-685.7 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Accelerate Diagnostics's EV-to-EBITDA for today is:
Accelerate Diagnostics's current Enterprise Value is MXN946.6 Mil.
Accelerate Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-621.2 Mil.
Accelerate Diagnostics's current Enterprise Value is MXN946.6 Mil.
Accelerate Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN220.5 Mil.
Accelerate Diagnostics's current Enterprise Value is MXN946.6 Mil.
Accelerate Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-445.8 Mil.
Accelerate Diagnostics's current Enterprise Value is MXN946.6 Mil.
Accelerate Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-454.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics Enterprise Value Related Terms
Accelerate Diagnostics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Accelerate Diagnostics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:AXDX vs MSIU, BIOLQ, AFIB: Enterprise Value Comparison
For the Medical Devices subindustry, Accelerate Diagnostics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accelerate Diagnostics Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's Enterprise Value falls into.
Accelerate Diagnostics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Accelerate Diagnostics's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of MXN946.6 Mil mean?
Accelerate Diagnostics (MEX:AXDX) has a Enterprise Value of MXN946.6 Mil as of Sep. 09, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Enterprise Value too high?
Accelerate Diagnostics' current Enterprise Value is MXN946.6 Mil. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Enterprise Value compare to MSIU and BIOLQ?
Accelerate Diagnostics' Enterprise Value of MXN946.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Accelerate Diagnostics and its competitors. Accelerate Diagnostics's current Enterprise Value is MXN946.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Enterprise Value of MXN946.6 Mil. The current Enterprise Value is MXN946.6 Mil. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Enterprise Value is MXN946.6 Mil as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score
Get the complete analysis for MEX:AXDX
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AXDX has been successfully added to your 
